Abstract Body

CD4 mimic compounds (CD4mc) that inhibit the interaction of gp120 with CD4 are expected as an entry inhibitor. Furthermore, CD4mc induce structural changes in gp120 trimer through binding to the CD4 binding (Phe43)-cavity of gp120. We recently developed YIR-821, a novel CD4mc, which showed more potent and less cytotoxic activities than original CD4mc NBD-556. Here we examined anti-HIV-1 activities of YIR-821 including enhancing activities for neutralization and ADCC (antibody-dependent cellular cytotoxicity) against a variety of viruses.

We used pseudovirus panels of HIV-1 strains (standard panel B/ panel C/global standard panel) to investigate the spectrum of YIR-821 for neutralization/binding enhancement as well as activities as an entry inhibitor. Synergistic effects in neutralization were examined for antibodies targeting V3/CD4bs/CD4i regions and calculated by R package ‘SynergyFinder’. To evaluate ADCC, CEM-NKR-CCR5-luc T-cell line infected with HIV-1 BaL was prepared as target and incubated with antibodies and effector cells (CD16 expressing KHYG-1 NK cell line) for 8 hours, then relative luminescent activity was measured.

We found broad and potent anti-HIV-1 activities of YIR-821 as an entry inhibitor against panels of subtype-B and C virus. YIR-821 induced exposure of conformational epitopes on gp120 was observed not only in subtypes B and C, but also subtypes A and B/C, which were relatively resistant to the inhibitory activity by YIR-821. Interestingly, YIR-821 treatment alone is not effective against JR-FL (subtype B, but uniquely YIR-821 resistant strain), but the combination of YIR-821 with anti-V3/CD4i antibodies showed synergistically neutralization, suggesting some difference in the process of these two anti-HIV mechanisms. Moreover, we observed potent enhancement for ADCC activity of anti-V3/CD4i antibodies against HIV-1 infected cells in the presence of YIR-821.

These data taken together suggest that YIR-821 has enhancing activity to ADCC with an excellent property of neutralization-enhancing activities for broad spectrum of HIV-1 in vitro. Combinational use of YIR-821 and anti-V3/CD4i antibodies represents a promising candidate for prevention or treatment of HIV-1 infection.